Eikon Therapeutics, Inc.
EIKNDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
How EIKN's past catalysts played out
EIK1001
Advanced Melanoma
Paclitaxel + Carboplatin
Non Small Cell Lung Cancer (Squamous or Non Squamous)
EIK1004-001 (IMP1707-001)
Advanced Solid Tumors
IMP1734
Advanced Solid Tumor
EIK1005
Advanced Solid Tumors
BDB001
Tumor, Solid
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EIK1001 | Phase 3 | Advanced Melanoma | - | - |
Paclitaxel + Carboplatin | Phase 3 | Non Small Cell Lung Cancer (Squamous or Non Squamous) | - | - |
EIK1004-001 (IMP1707-001) | Phase 2 | Advanced Solid Tumors | - | - |
IMP1734 | Phase 2 | Advanced Solid Tumor | - | - |
EIK1005 | Phase 2 | Advanced Solid Tumors | - | - |
BDB001 | Phase 2 | Tumor, Solid | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Eikon Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Eikon Therapeutics, Inc.'s (EIKN) pipeline across Phase 3, Phase 2. Its lead program is EIK1001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eikon Therapeutics, Inc.'s next FDA catalyst?→
Eikon Therapeutics, Inc.'s (EIKN) next tracked catalyst is a Conference expected September 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EIKN biotech catalysts?→
Add EIKN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eikon Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.